Reading ATOS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ATOS free→Reading ATOS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ATOS free→QuarterlyIQ Insights · ATOS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On June 10, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors, providing for the issuance and sale by the Company, in a registered direct offering (the “Offering”), of (i) 1,363,638 shares (the “Shares”) of the Company’s common stock, par value $0.18 (“Common Stock”) and (ii) Series A warrants to purchase up to 1,363,638 shares of Common Stock and shor…
Results of Operations and Financial Condition. On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for pu…
Other Events. On April 16, 2026, Atossa Therapeutics, Inc. (the “Company”) announced that on April 13, 2026, the Company entered into a Settlement Agreement (the “Settlement Agreement”) with Intas Pharmaceuticals Ltd. (“Intas”) and Jina Pharmaceuticals, Inc., which is intended to resolve patent disputes related to Endoxifen-related intellectual property, including pending proceedings before the U.S. Patent and Trademark Office Patent Trial and Appeal Board (“PTAB”). As previously disclosed by…
Results of Operations and Financial Condition. On March 25, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the fourth quarter and year ended December 31, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be…
Termination of a Material Definitive Agreement. On February 19, 2026, the Company delivered written notice to Jefferies LLC indicating that it is terminating the Open Market Sale Agreement SM (the “Prior Agreement”) by and between the Company and Jefferies LLC, dated November 19, 2024, effective as of February 19, 2026. The Company is not subject to any termination penalties related to the termination of the Prior Agreement. The Company did not undertake any sales of its common stock pursuant…
Entry Into a Material Definitive Agreement. On February 20, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into the At the Market Offering Agreement, dated February 20, 2026 (the “Sales Agreement”), with Rodman & Renshaw LLC (the “Sales Agent”), pursuant to which the Company may offer and sell from time to time up to $50,000,000 of shares of the Company’s common stock, par value $0.18 per share (the “Shares”), through the Sales Agent as agent or principal. The offering and sale of th…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 17, 2026, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on February 21, 2025, the Company was notified…
Material Modification to Rights of Security Holders. Following the Special Meeting, the Company’s Board of Directors approved a reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.18 per share (the “Common Stock”), at a ratio of 15:1 (the “Reverse Stock Split Ratio”) with an effective time of 12:01 a.m. Eastern Time on February 2, 2026 (the “Effective Time”). To effect the Reverse Stock Split, the Company filed an amendment to its Amended and Restated C…
of this Form 8-K and in Exhibit 99.1 attached hereto regarding the Company’s estimated cash and cash equivalents balance as of December 31, 2025 is preliminary, unaudited and subject to finalization of its full financial results and completion of the Company’s financial statement closing procedures for the fourth quarter and fiscal year ended December 31, 2025. This estimate also does not present all information necessary for an understanding of the Company’s financial condition as of Decembe…
Results of Operations and Financial Condition. On November 12, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” fo…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2025 (the “Effective Date”), Atossa Therapeutics, Inc. (the “Company”) announced the appointment of Mr. Mark Daniel as the Chief Financial Officer of the Company (“CFO”), effective immediately. In his role as CFO, Mr. Daniel also will act as the Company’s principal accounting officer (“PAO”). Mr. Daniel succeeds Ms. Heather Rees, who…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $…
Results of Operations and Financial Condition. On August 12, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended June 30, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpo…
Results of Operations and Financial Condition. On May 13, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpose…
Results of Operations and Financial Condition. On March 25, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the year ended December 31, 2024 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpo…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share f…
Other Events On January 30, 2025, Atossa Therapeutics, Inc. (the "Company") issued a press release that announced the Patent Trial and Appeal Board's ("PTAB") final written decision in PGR2023-00043 which found that all claims under U.S. Patent No. 11,572,334 were unpatentable. While the Company disagrees with the decision and believes there are appealable issues, the Company will not be pursuing an appeal from the PTAB decision, given the cost and time involved. Instead, the Company intends…
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.